Summary of WuXi AppTec Co Ltd Conference Call Company Overview - **Company**: WuXi AppTec Co Ltd - **Industry**: China Healthcare - **Stock Rating**: Overweight - **Price Target**: HK$145.00 - **Current Price**: HK$117.50 - **Market Capitalization**: Rmb285,728 million - **Fiscal Year Ending**: December 2025 Key Financial Metrics - **Revenue Growth**: Projected revenue growth of over 20% for the Chemistry segment and over 30% for TIDES in 2026 [2][4] - **Capex Allocation**: Projected capital expenditure of Rmb6.5-7.5 billion for 2026, representing a 17% to 35% increase compared to 2025, with 60-70% allocated to CDMO capacity [2] - **Backlog**: Continuing operations backlog reached Rmb58.0 billion as of end-2025, up 29% YoY [2] - **Gross Margin**: Chemistry segment gross margin expected to remain stable at 45-50% in 2026 [2] Growth Drivers - **Solid Phase Peptide Capacity**: Projected capacity to reach 130,000L by 2026, indicating strong growth potential in peptide synthesis [2] - **Outsourcing Trend**: Increasing propensity for multinational corporations (MNCs) to outsource, contributing to revenue growth [7] - **Project Portfolio**: A large project portfolio with stable revenue streams from 83 commercial contracts, making the company less sensitive to biopharma funding volatility [7] Market Dynamics - **Global Supply Shortage**: Observed global supply shortages for advanced modalities, such as GLP-1 peptides, where China offers cost and efficiency advantages [7] - **Earnings Performance**: Consistent earnings beats against consensus estimates throughout 2025, driven by mid-to-late and commercial-stage projects [7] Risks and Considerations - **Market Risks**: Potential margin pressure from US business, global competition, and geopolitical risks [11] - **Operational Risks**: Talent turnover and IP protection issues could impact operational efficiency [11] Valuation Methodology - **Discounted Cash Flow**: Price target derived from a discounted cash flow methodology with a WACC of 10% and a terminal growth rate of 4% [8] Conclusion - WuXi AppTec is positioned strongly within the China healthcare sector, with robust growth prospects driven by increasing outsourcing trends and a solid project pipeline. The company’s financial metrics indicate a stable outlook, although it faces various operational and market risks that could impact its performance in the coming years.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年4月1日 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2026 年 3 月 24 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明 康德新药开发股份有限公司 2025 年年度报告》。为了便于广大投资者更全面深入 地了解本公司 2025 年度业绩和经营情况，本公司拟于 2026 年 4 月 13 日（星期 一）上午 10:00-11:00 召开业绩说明会，就投资者普遍 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | 備註： 第 1 頁 共 11 頁 v 1.2.1 FF3 ...

Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [11] Core Insights - The innovative chain sector is entering a new growth cycle driven by both domestic and international demand, with significant improvements expected in China's innovative drug R&D investment starting in 2025 [2][6] - Chinese innovative drug companies are expected to see a substantial increase in available funds, with a projected total of 201.5 billion yuan in IPO fundraising and financing activities in 2025, marking a 145% year-on-year increase [6] - The report highlights the strong performance of CDMO companies, with significant order improvements anticipated by mid-2024, and a positive trend in their financial performance [7] - The innovative drug sector is entering a realization phase with low valuation levels, and numerous catalysts expected in Q2 2026, suggesting a favorable outlook for investments in this area [8] Summary by Sections Domestic Demand - By 2025, the investment climate for innovative drug R&D in China is expected to improve, leading to a new cycle of prosperity in the innovative drug industry [6] - The funding available to Chinese pharmaceutical companies is increasing, with a projected 880.5 billion yuan in potential milestone payments from external business development (BD) activities, a 185.9% year-on-year increase [6] International Demand - CDMO companies focused on overseas revenue are expected to see significant improvements in new orders starting from Q2 2024, with year-on-year growth rates recovering to over 15% [7] - WuXi AppTec's backlog is projected to reach 58 billion yuan by the end of 2025, reflecting a 28.8% year-on-year increase, with expected revenue growth of 18-22% in 2026 [7] Innovative Drug Sector - The innovative drug sector is entering a realization phase with low valuations, supported by a series of policy measures that have been implemented since 2024 [8] - The number of Chinese companies participating in international academic conferences is increasing, with over 100 expected to present nearly 400 research outcomes in 2026 [8] Technological Advancements - Chinese pharmaceutical companies are rapidly enhancing their global competitiveness, with innovative technologies such as second-generation ADCs and molecular therapies being developed at a leading global level [9] - The report suggests that the outbound business development strategies are diversifying, including mergers and collaborations, which could enhance the global presence of Chinese pharmaceutical companies [9]

可持續發展報告 2025 無錫藥明康德新藥開發股份有限公司 目錄 | 關於本報告 | 01 | | --- | --- | | 董事長兼首席執行官致辭 | 02 | | 2025 可持續發展亮點績效 | 03 | | 2025 可持續發展評級表現與國際權威認可 | 04 | | 關於藥明康德 | 05 | | 企業管治 | 06 | | 可持續發展戰略 | 12 | | 績效表 | 96 | | --- | --- | | 附錄 | 103 | 責任公民 | 反腐敗與反賄賂 | 21 | | --- | --- | | 公平競爭 | 26 | | 資訊安全 | 27 | 賦能客戶 | 產品與服務品質 | 36 | | --- | --- | | 研發倫理 | 41 | | 可持續供應鏈 | 44 | 守護地球 | 氣候變化 | 51 | | --- | --- | | 排放與廢棄物管理 | 63 | | 資源管理 | 71 | | 生態系統和生物多樣性 | 76 | 以人為本 | 人才吸引與發展 | 79 | | --- | --- | | 職業健康與安全 | 89 | | 社區參與 | 93 | 關於藥明康 ...

http://www.wuxiapptec.com 2025 WuXi AppTec Co., Ltd.* 無錫藥明康德新藥開發股份有限公司 WuXi AppTec Co., Ltd.* 股份代碼：2359 （於中華人民共和國註冊成立的股份有限公司） 年度 報告 年度 報告 2025 2025 中國上海外高橋自貿區富特中路288號 郵編：200131 電話：+86 (21) 5046-1111 (總機) 傳真：+86 (21) 5046-1000 年度報告 無錫藥明康德新藥開發股份有限公司 WuXi AppTec Co., Ltd.* C M Y CM MY CY CMY K ai177458382733_Wuxi Apptec AR2025 Cover V03B_15mm_CHI_OP.pdf 1 27/3/2026 11:57 AM zz00 IFC (e).indd 2 27/3/2026 12:00 PM 目錄 | 公司資料 | 2 | | --- | --- | | 董事長報告書 | 4 | | 財務摘要 | 5 | | 管理層討論與分析 | 6 | | 五年統計 | 36 | | 董事、監事及高級 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2026-016 无锡药明康德新药开发股份有限公司 关于召开 2025 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2026 年 3 月 24 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明 康德新药开发股份有限公司 2025 年年度报告》。为了便于广大投资者更全面深入 地了解本公司 2025 年度业绩和经营情况，本公司拟于 2026 年 4 月 13 日（星期 一）上午 10:00-11:00 召开业绩说明会，就投资者普遍关心的问题进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2025 年度业 绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普遍关注 的问题进行回答。 （三）会议召开方式：上证路演中心视频直播和网络互动 三、参加人员 本公司执行董事、联席首席执行官陈民章博士，执行 ...

美伊冲突释放缓和信号，今日亚太股市集体反弹，生物医药板块再度大涨！同类0.15%最低档费率的恒生生物 科技ETF汇添富（513280）大涨近6%，盘中放量成交超2.2亿元！热门成分股多数大涨，三生制药涨超11%， 康方生物、信达生物、药明生物涨超6%，药明康德涨超5%（标的指数成分股仅做展示，不作为个股推介）。 A股方面，生物医药ETF汇添富（159839）大涨近4%强势冲击四连阳，近60日净流入超1.8亿元！热门成分股 多数飘红，百利天恒涨超11%，凯莱英二连板，荣昌生物、君实生物-U涨超9%（标的指数成分股仅做展示， 不作为个股推介）。 【盈利拐点+出海加速+学术会议，创新药催化密集！】 方正证券指出，创新药受"盈利拐点+出海加速+数据催化"密集，兼具战争免疫属性，继续强烈看好： 1）创新药进入盈利周期，头部创新药公司密集进入盈亏平衡点。龙头创新药公司百济神州、信达生物等率先 实现盈利。创新药回调超半年，向下空间有限，且基本面基本不受美伊战争和经贸关系影响，具备很强的避险 属性。且与2022年加息周期所处时期不同，创新药如今已进入盈利周期，具备自身造血能力，估值受降息预期 变化影响大幅减弱。 3） 数据催 ...

Group 1: Biopharmaceutical Research - WuXi AppTec, as a global CRDMO leader, exceeded its revenue guidance for 2025, with a significant profit margin increase and a strong Tides business, reporting a 28% increase in backlog orders by the end of 2025, and expects a revenue growth of 18-22% in 2026 [1][3][4] - The company achieved a total revenue of RMB 45.46 billion in 2025, a year-on-year increase of 15.8%, and a net profit of RMB 19.15 billion, up 102.7% year-on-year, with adjusted Non-IFRS net profit rising by 41.3% [3][4] Group 2: Military Industry Research - The National Development and Reform Commission and the Ministry of Finance announced an optimization of the radio frequency occupation fee standards, which is expected to significantly reduce satellite internet frequency fees, accelerating the market penetration of satellite terminal applications [2][7][21] - The new fee structure will change the cost burden from end-users to satellite operators, facilitating the proliferation of satellite terminals and potentially lowering costs for high-frequency applications [8][21] Group 3: Home Appliance Research - TCL Electronics reported a strong performance in 2025, with revenue of HKD 114.58 billion, a year-on-year increase of 15.4%, and an adjusted net profit of HKD 2.51 billion, up 56.5% [9][10] - The company is focusing on high-end and global strategies, with a continuous increase in market share and an improved product structure leading to a significant enhancement in TV gross margins [11][12] Group 4: Food and Beverage Research - The demand for probiotics is expanding, driven by new channels like Douyin and emerging needs for weight loss, with a focus on the second-generation probiotic AKK, which is expected to accelerate market education and demand release [13][14] - The market for probiotic health products is projected to grow, with a 6% increase in scale to RMB 16 billion in 2025, and a notable 40% growth in GMV through Douyin [13][14]

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% by the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised guidance. The net profit attributable to shareholders reached 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY for 2026, 2027, and 2028, respectively, with growth rates of 15.3%, 14.8%, and 11.2%. The net profit attributable to shareholders is expected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% [12][13]. - The adjusted Non-IFRS gross margin improved to 48.2%, a year-on-year increase of 6.6 percentage points, driven by higher capacity utilization and an increase in high-margin business [12]. Business Performance - The chemical business generated revenue of 36,470 million CNY, a 25.5% year-on-year increase. The small molecule CDMO pipeline expanded, with revenue from small molecule D&M business reaching 19,920 million CNY, up 11.4% year-on-year [12]. - The Tides business saw revenue of 11,370 million CNY, a remarkable growth of 96% year-on-year, with a backlog of orders increasing by 20.2%. The number of clients for TIDES D&M services rose by 25%, and the number of service molecules increased by 45% [12].